Fundies. English
Segment disclosures
Company overviewBiogen Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
34 dimension combinations 121 retained observations 13 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Contract Manufacturing Royalty And Other Revenue · Europe Excluding Germany · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;srt:StatementGeographicalAxis=biib:EuropeExcludingGermanyMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 10800000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 400000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 11700000 | USD | 20260206 | Open filing evidence |
Contract Manufacturing Royalty And Other Revenue · Segment Geographical Groups Of Countries Group Other · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;srt:StatementGeographicalAxis=biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20260206 | Open filing evidence |
Contract Manufacturing Royalty And Other Revenue · DE · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;srt:StatementGeographicalAxis=country:DE;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20260206 | Open filing evidence |
Contract Manufacturing Royalty And Other Revenue · US · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 414700000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 395000000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 673600000 | USD | 20260206 | Open filing evidence |
Contract Manufacturing Royalty And Other Revenue · Asia · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;srt:StatementGeographicalAxis=srt:AsiaMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 307400000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 257200000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 214000000 | USD | 20260206 | Open filing evidence |
Contract Manufacturing Royalty And Other Revenue · Reportable Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 732900000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 652600000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 899300000 | USD | 20260206 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 485100000 | USD | 20250212 | Open filing evidence |
Revenues From Anti CD20 Therapeutic Programs · Europe Excluding Germany · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;srt:StatementGeographicalAxis=biib:EuropeExcludingGermanyMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 1800000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 600000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 400000 | USD | 20260206 | Open filing evidence |
Revenues From Anti CD20 Therapeutic Programs · Segment Geographical Groups Of Countries Group Other · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;srt:StatementGeographicalAxis=biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 83400000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 75700000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 70700000 | USD | 20260206 | Open filing evidence |
Revenues From Anti CD20 Therapeutic Programs · DE · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;srt:StatementGeographicalAxis=country:DE;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20260206 | Open filing evidence |
Revenues From Anti CD20 Therapeutic Programs · US · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 1775400000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1673600000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1618500000 | USD | 20260206 | Open filing evidence |
Revenues From Anti CD20 Therapeutic Programs · Asia · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;srt:StatementGeographicalAxis=srt:AsiaMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20260206 | Open filing evidence |
Revenues From Anti CD20 Therapeutic Programs · Reportable Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 1860600000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1749900000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1689600000 | USD | 20260206 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 1700500000 | USD | 20250212 | Open filing evidence |
Product · Europe Excluding Germany · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;srt:StatementGeographicalAxis=biib:EuropeExcludingGermanyMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 1871600000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2171500000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2127400000 | USD | 20260206 | Open filing evidence |
Product · Segment Geographical Groups Of Countries Group Other · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;srt:StatementGeographicalAxis=biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 427800000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 482200000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 460500000 | USD | 20260206 | Open filing evidence |
Product · DE · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;srt:StatementGeographicalAxis=country:DE;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 853000000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 955600000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 868000000 | USD | 20260206 | Open filing evidence |
Product · US · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 3547900000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 3237300000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 3141400000 | USD | 20260206 | Open filing evidence |
Product · Asia · Reportable Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;srt:StatementGeographicalAxis=srt:AsiaMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 419100000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 366900000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 649400000 | USD | 20260206 | Open filing evidence |
Product · Reportable Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 7119400000 | USD | 20260206 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 7213500000 | USD | 20260206 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 7246700000 | USD | 20260206 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 7987800000 | USD | 20250212 | Open filing evidence |
Europe Excluding Germany · Contract Manufacturing Royalty And Other Revenue · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=biib:EuropeExcludingGermanyMember;srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 400000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 11700000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 11700000 | USD | 20250212 | Open filing evidence |
Europe Excluding Germany · Revenues From Anti CD20 Therapeutic Programs · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=biib:EuropeExcludingGermanyMember;srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 600000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 400000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 100000 | USD | 20250212 | Open filing evidence |
Europe Excluding Germany · Product · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=biib:EuropeExcludingGermanyMember;srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 2171500000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2127400000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 2401300000 | USD | 20250212 | Open filing evidence |
Segment Geographical Groups Of Countries Group Other · Contract Manufacturing Royalty And Other Revenue · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember;srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 0 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 0 | USD | 20250212 | Open filing evidence |
Segment Geographical Groups Of Countries Group Other · Revenues From Anti CD20 Therapeutic Programs · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember;srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 75700000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 70700000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 64000000 | USD | 20250212 | Open filing evidence |
Segment Geographical Groups Of Countries Group Other · Product · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember;srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 482200000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 460500000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 518900000 | USD | 20250212 | Open filing evidence |
DE · Contract Manufacturing Royalty And Other Revenue · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:DE;srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 0 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 0 | USD | 20250212 | Open filing evidence |
DE · Revenues From Anti CD20 Therapeutic Programs · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:DE;srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 0 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 0 | USD | 20250212 | Open filing evidence |
DE · Product · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:DE;srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 955600000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 868000000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 926200000 | USD | 20250212 | Open filing evidence |
US · Contract Manufacturing Royalty And Other Revenue · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 395000000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 673600000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 425800000 | USD | 20250212 | Open filing evidence |
US · Revenues From Anti CD20 Therapeutic Programs · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 1673600000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1618500000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 1636400000 | USD | 20250212 | Open filing evidence |
US · Product · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 3237300000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 3141400000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 3469300000 | USD | 20250212 | Open filing evidence |
Asia · Contract Manufacturing Royalty And Other Revenue · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaMember;srt:ProductOrServiceAxis=biib:ContractManufacturingRoyaltyAndOtherRevenueMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 257200000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 214000000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 47600000 | USD | 20250212 | Open filing evidence |
Asia · Revenues From Anti CD20 Therapeutic Programs · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaMember;srt:ProductOrServiceAxis=biib:RevenuesFromAntiCD20TherapeuticProgramsMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 0 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 0 | USD | 20250212 | Open filing evidence |
Asia · Product · Reportable Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaMember;srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 366900000 | USD | 20250212 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 649400000 | USD | 20250212 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 672100000 | USD | 20250212 | Open filing evidence |
Reportable Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=biib:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 2804100000 | USD | 2026-10-28 · 10:23:04.000Z | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 8017900000 | USD | 2026-10-28 · 10:23:04.000Z | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 2736000000 | USD | 20260729 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 5213800000 | USD | 20260729 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 2477800000 | USD | 20260429 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 9890600000 | USD | 20260206 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 2534700000 | USD | 2026-10-28 · 10:23:04.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 7611200000 | USD | 2026-10-28 · 10:23:04.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 2645500000 | USD | 20260729 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 5076500000 | USD | 20260729 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 2431000000 | USD | 20260429 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 9675900000 | USD | 20260206 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 2465800000 | USD | 20251030 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 7221200000 | USD | 20251030 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 2464900000 | USD | 20250731 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 4755400000 | USD | 20250731 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 2290500000 | USD | 20250501 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 9835600000 | USD | 20260206 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 10173400000 | USD | 20250212 | Open filing evidence |